Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853213 | 0.96 | TLR7 (0.57) | TLR7TLR8DHFRPKM | |
| SCHEMBL855086 | 0.89 | DHFR (0.47) | TLR7TLR8DHFRPKM | |
| SCHEMBL854017 | 0.89 | DHFR (0.62) | TLR7TLR8DHFR | |
| SCHEMBL854279 | 0.88 | DHFR (0.45) | TLR7TLR8DHFRLTA4H | |
| SCHEMBL853935 | 0.85 | TLR7 (0.51) | TLR7TLR8DNM2 | |
| SCHEMBL853483 | 0.85 | DHFR (0.62) | TLR7DHFR | |
| SCHEMBL854178 | 0.84 | ALDH1A1 (0.51) | TLR7TLR8DHFR | |
| SCHEMBL3699620 | 0.84 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL853436 | 0.83 | TLR7 (0.54) | TLR7LTA4H | |
| SCHEMBL861355 | 0.83 | TLR7 (0.56) | TLR7TLR8LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885DHFR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.